Logo image of ZLAB

ZAI LAB LTD-ADR (ZLAB) Stock Fundamental Analysis

NASDAQ:ZLAB - Nasdaq - US98887Q1040 - ADR - Currency: USD

34.08  -4.64 (-11.98%)

Premarket: 34.61 +0.53 (+1.56%)

Fundamental Rating

4

Overall ZLAB gets a fundamental rating of 4 out of 10. We evaluated ZLAB against 551 industry peers in the Biotechnology industry. While ZLAB seems to be doing ok healthwise, there are quite some concerns on its profitability. ZLAB is valued quite expensive, but it does show an excellent growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

ZLAB had negative earnings in the past year.
In the past year ZLAB has reported a negative cash flow from operations.
In the past 5 years ZLAB always reported negative net income.
ZLAB had a negative operating cash flow in each of the past 5 years.
ZLAB Yearly Net Income VS EBIT VS OCF VS FCFZLAB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -200M -400M -600M

1.2 Ratios

ZLAB has a better Return On Assets (-21.48%) than 77.31% of its industry peers.
ZLAB has a Return On Equity of -31.09%. This is in the better half of the industry: ZLAB outperforms 75.86% of its industry peers.
Industry RankSector Rank
ROA -21.48%
ROE -31.09%
ROIC N/A
ROA(3y)-30.1%
ROA(5y)-30.96%
ROE(3y)-38.33%
ROE(5y)-37.81%
ROIC(3y)N/A
ROIC(5y)N/A
ZLAB Yearly ROA, ROE, ROICZLAB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60

1.3 Margins

ZLAB has a Gross Margin of 63.62%. This is in the better half of the industry: ZLAB outperforms 79.67% of its industry peers.
In the last couple of years the Gross Margin of ZLAB has declined.
The Profit Margin and Operating Margin are not available for ZLAB so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 63.62%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.36%
GM growth 5Y-2.26%
ZLAB Yearly Profit, Operating, Gross MarginsZLAB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50K -100K

More info and screens

4

2. Health

2.1 Basic Checks

ZLAB does not have a ROIC to compare to the WACC, probably because it is not profitable.
ZLAB has more shares outstanding than it did 1 year ago.
The number of shares outstanding for ZLAB has been increased compared to 5 years ago.
The debt/assets ratio for ZLAB is higher compared to a year ago.
ZLAB Yearly Shares OutstandingZLAB Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
ZLAB Yearly Total Debt VS Total AssetsZLAB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

2.2 Solvency

An Altman-Z score of 4.43 indicates that ZLAB is not in any danger for bankruptcy at the moment.
ZLAB has a better Altman-Z score (4.43) than 75.50% of its industry peers.
A Debt/Equity ratio of 0.21 indicates that ZLAB is not too dependend on debt financing.
With a Debt to Equity ratio value of 0.21, ZLAB is not doing good in the industry: 70.42% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 0.21
Debt/FCF N/A
Altman-Z 4.43
ROIC/WACCN/A
WACC9.66%
ZLAB Yearly LT Debt VS Equity VS FCFZLAB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M -500M 1B

2.3 Liquidity

ZLAB has a Current Ratio of 3.26. This indicates that ZLAB is financially healthy and has no problem in meeting its short term obligations.
ZLAB has a Current ratio of 3.26. This is in the lower half of the industry: ZLAB underperforms 61.89% of its industry peers.
A Quick Ratio of 3.09 indicates that ZLAB has no problem at all paying its short term obligations.
The Quick ratio of ZLAB (3.09) is worse than 62.25% of its industry peers.
Industry RankSector Rank
Current Ratio 3.26
Quick Ratio 3.09
ZLAB Yearly Current Assets VS Current LiabilitesZLAB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

More info and screens

7

3. Growth

3.1 Past

ZLAB shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 31.43%, which is quite impressive.
Looking at the last year, ZLAB shows a very strong growth in Revenue. The Revenue has grown by 43.72%.
The Revenue has been growing by 98.34% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)31.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%20%
Revenue 1Y (TTM)43.72%
Revenue growth 3Y40.36%
Revenue growth 5Y98.34%
Sales Q2Q%22.19%

3.2 Future

The Earnings Per Share is expected to grow by 89.50% on average over the next years. This is a very strong growth
Based on estimates for the next years, ZLAB will show a very strong growth in Revenue. The Revenue will grow by 41.81% on average per year.
EPS Next Y41.13%
EPS Next 2Y45.88%
EPS Next 3Y53.48%
EPS Next 5Y89.5%
Revenue Next Year46.4%
Revenue Next 2Y51.51%
Revenue Next 3Y49.09%
Revenue Next 5Y41.81%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
ZLAB Yearly Revenue VS EstimatesZLAB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 1B 2B 3B
ZLAB Yearly EPS VS EstimatesZLAB Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 50 100

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

ZLAB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
With a Price/Forward Earnings ratio of 108.57, ZLAB can be considered very expensive at the moment.
ZLAB's Price/Forward Earnings ratio is rather cheap when compared to the industry. ZLAB is cheaper than 88.02% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 35.28, ZLAB is valued quite expensively.
Industry RankSector Rank
PE N/A
Fwd PE 108.57
ZLAB Price Earnings VS Forward Price EarningsZLAB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ZLAB Per share dataZLAB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6

4.3 Compensation for Growth

The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates ZLAB does not grow enough to justify the current Price/Earnings ratio.
ZLAB's earnings are expected to grow with 53.48% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y45.88%
EPS Next 3Y53.48%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ZLAB!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ZAI LAB LTD-ADR

NASDAQ:ZLAB (8/7/2025, 8:04:38 PM)

Premarket: 34.61 +0.53 (+1.56%)

34.08

-4.64 (-11.98%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-07 2025-08-07/bmo
Earnings (Next)11-10 2025-11-10
Inst Owners45.81%
Inst Owner Change-5.81%
Ins Owners1.3%
Ins Owner Change6.27%
Market Cap3.76B
Analysts78.46
Price Target40.07 (17.58%)
Short Float %3.9%
Short Ratio4.46
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)4.76%
Min EPS beat(2)-12.04%
Max EPS beat(2)21.57%
EPS beat(4)3
Avg EPS beat(4)15.62%
Min EPS beat(4)-12.04%
Max EPS beat(4)50.98%
EPS beat(8)5
Avg EPS beat(8)14.36%
EPS beat(12)9
Avg EPS beat(12)39.16%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-6.12%
Min Revenue beat(2)-10.58%
Max Revenue beat(2)-1.65%
Revenue beat(4)1
Avg Revenue beat(4)-2.51%
Min Revenue beat(4)-10.58%
Max Revenue beat(4)4.31%
Revenue beat(8)3
Avg Revenue beat(8)-0.72%
Revenue beat(12)5
Avg Revenue beat(12)-1.95%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-4.52%
PT rev (3m)7.31%
EPS NQ rev (1m)0%
EPS NQ rev (3m)16.39%
EPS NY rev (1m)0%
EPS NY rev (3m)-4.52%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-3.49%
Revenue NY rev (1m)0.76%
Revenue NY rev (3m)0.5%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 108.57
P/S 8.99
P/FCF N/A
P/OCF N/A
P/B 4.64
P/tB 5
EV/EBITDA N/A
EPS(TTM)-2.35
EYN/A
EPS(NY)0.31
Fwd EY0.92%
FCF(TTM)-2.16
FCFYN/A
OCF(TTM)-1.69
OCFYN/A
SpS3.79
BVpS7.34
TBVpS6.81
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -21.48%
ROE -31.09%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 63.62%
FCFM N/A
ROA(3y)-30.1%
ROA(5y)-30.96%
ROE(3y)-38.33%
ROE(5y)-37.81%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.36%
GM growth 5Y-2.26%
F-Score5
Asset Turnover0.36
Health
Industry RankSector Rank
Debt/Equity 0.21
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 425.79%
Cap/Sales 12.52%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.26
Quick Ratio 3.09
Altman-Z 4.43
F-Score5
WACC9.66%
ROIC/WACCN/A
Cap/Depr(3y)305.55%
Cap/Depr(5y)287.72%
Cap/Sales(3y)10.07%
Cap/Sales(5y)13.03%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)31.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%20%
EPS Next Y41.13%
EPS Next 2Y45.88%
EPS Next 3Y53.48%
EPS Next 5Y89.5%
Revenue 1Y (TTM)43.72%
Revenue growth 3Y40.36%
Revenue growth 5Y98.34%
Sales Q2Q%22.19%
Revenue Next Year46.4%
Revenue Next 2Y51.51%
Revenue Next 3Y49.09%
Revenue Next 5Y41.81%
EBIT growth 1Y29.13%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year47.05%
EBIT Next 3Y36.62%
EBIT Next 5Y32.27%
FCF growth 1Y35.17%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y46.69%
OCF growth 3YN/A
OCF growth 5YN/A